Effect of Montmorillonite powder on intestinal mucosal barrier in children with abdominal Henoch-Schonlein purpura: A randomized controlled study

• Published in: Medicine (Baltimore) 2018-09, Vol.97 (39), p.e12577-e12577
• Main Authors: Gao, Xiaolin, Miao, Ruixue, Tao, Yuhong, Chen, Xiuying, Wan, Chaomin, Jia, Ruizhen
• Format: Article
• Language: English
• Subjects: Amine Oxidase (Copper-Containing) - blood; Antidotes - therapeutic use; Bentonite - therapeutic use; Child; Clinical Trial/Experimental Study; Endotoxins - blood; Humans; Intestinal Mucosa - drug effects; Lactic Acid - blood; Powders; Purpura, Schoenlein-Henoch - blood; Purpura, Schoenlein-Henoch - complications; Purpura, Schoenlein-Henoch - drug therapy
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000012577

Our previous studies found that intestinal barrier function has been changed in children with abdominal Henoch-Schonlein purpura (HSP). Montmorillonite has been shown to be protective for digestive tract mucosa. The present study aimed to investigate whether Montmorillonite powder could improve the intestinal mucosal barrier function in children with abdominal HSP. Using a randomized controlled study design, we compared plasma levels of diamine oxidase (DAO), D-lactate, and endotoxin in children with abdominal HSP before and after Montmorillonite powder treatment. Among 28 patients in experimental group and 30 in control group, there was no significant difference in age, sex, height, weight, and course of disease between 2 groups (P > .05). Before treatment, there was no statistical difference in DAO, D-lactic acid, and endotoxin between experimental group and the control group (P > .05). However, significant differences were detected for DAO and D-lactate after treatment in comparison to before treatment in the Montmorillonite experimental group (P  .05). Montmorillonite powder is effective in the treatment of HSP via maintaining intestinal mucosal barrier function.